The researchers constructed a high-resolution single-cell atlas from more than 240,000 cells obtained from patients with gastric cancer. Single-cell RNA sequencing enabled them to examine gene-expression programs in individual cells rather than averaging signals across entire tumor samples. This approach revealed extensive cellular diversity within the tumor microenvironment, including multiple macrophage populations, T-cell states and metabolic programs associated with treatment response. Instead of finding that one immune cell type alone predicted outcome, the investigators identified a functional relationship between two macrophage states characterized by high expression of CXCL10 and OLR1.

Macrophages are adaptable immune cells that can respond to signals from cancer cells, stromal tissue and other immune populations. In the gastric tumors examined in the study, Mac-CXCL10 and Mac-OLR1 represented distinct functional states. The relative abundance of these populations was more informative than the simple presence or absence of either one. Tumors with a higher Mac-CXCL10/Mac-OLR1 ratio were more likely to respond to ICB therapy and were associated with longer progression-free survival. This ratio therefore emerged as a potential indicator of the immune conditions that make a tumor more receptive to checkpoint blockade.

The favorable macrophage state was closely linked to a population of interferon-responsive CD8-positive T cells. Interferons are signaling proteins that help coordinate antiviral and antitumor immunity by regulating antigen presentation, immune-cell recruitment and cytotoxic activity. The study suggests that Mac-CXCL10 cells and interferon-responsive CD8-positive T cells form a coordinated “interferon-responsive immune hub” within the tumor microenvironment. In this setting, macrophage-derived signals may help sustain T-cell activation, while activated T cells reinforce an inflammatory circuit capable of supporting tumor-cell recognition and destruction.

The opposing Mac-OLR1 state was associated with lipid-related metabolic programs and features of immune suppression. OLR1, also known as the lectin-like oxidized low-density lipoprotein receptor-1, can bind oxidized lipid particles and is involved in cellular responses to lipid stress. The findings indicate that the accumulation of oxidized lipids in the tumor environment may contribute to the development or maintenance of this macrophage population. Such metabolic pressure could alter macrophage gene expression and behavior, shifting the immune ecosystem away from effective T-cell stimulation.

A central mechanism identified by the researchers involved prostaglandin E₂, or PGE₂, a lipid-derived signaling molecule with broad effects on inflammation and immunity. Mac-OLR1 macrophages were linked to increased PGE₂-related activity. PGE₂ can influence immune-cell migration, cytokine production and T-cell function through signaling pathways that regulate intracellular cyclic AMP and downstream transcriptional responses. In the context of this study, PGE₂ was associated with suppression of interferon signaling in CD8-positive T cells, potentially weakening the production of effector molecules and reducing the ability of these cells to attack malignant cells.

This macrophage–T-cell relationship offers a possible explanation for why some gastric tumors fail to respond even when immune checkpoint molecules are therapeutically blocked. ICB can remove inhibitory signals such as those mediated by PD-1 or related pathways, but this intervention may be insufficient if the surrounding tissue continues to deliver metabolic and inflammatory signals that disable T cells. A PGE₂-rich environment could therefore act as an additional layer of immune resistance, limiting the restoration of T-cell activity after checkpoint inhibition.

The study also raises the possibility of combining immunotherapy with interventions aimed at the tumor’s lipid metabolism or PGE₂ signaling. Strategies that reduce oxidized-lipid stress, alter OLR1-associated macrophage programs or inhibit PGE₂ production and activity could, in principle, shift the macrophage balance toward a more immune-supportive state. Such approaches might enhance the effect of checkpoint blockade, although the study does not establish a treatment regimen for patients. The safety, timing and selectivity of any macrophage- or PGE₂-targeted therapy will require careful evaluation, since these pathways also participate in normal tissue repair and inflammatory control.

The investigators emphasize that their findings require further clinical validation before the macrophage ratio can be used as a routine biomarker. Nevertheless, the work provides a detailed framework for understanding gastric cancer immunotherapy resistance as an ecosystem-level problem. The outcome of treatment may depend not simply on whether immune cells are present, but on how macrophage states, lipid metabolism and T-cell interferon signaling interact within individual tumors. By identifying the Mac-CXCL10/Mac-OLR1 balance and its connection to PGE₂-mediated suppression, the study points toward a more precise form of immunotherapy in which the immune environment itself becomes a therapeutic target.

Subject of Research:
Macrophage states, tumor microenvironment, CD8⁺ T-cell immunity and immunotherapy response in gastric cancer.

Web References:
https://doi.org/10.1016/j.scib.2026.07.049

References:
Science Bulletin, DOI: 10.1016/j.scib.2026.07.049

Image Credits:
© Science Bulletin; created with BioRender.com.

Keywords:
Gastric cancer, immunotherapy, immune checkpoint blockade, tumor microenvironment, macrophages, CXCL10, OLR1, CD8⁺ T cells, interferon signaling, prostaglandin E₂, oxidized lipids, immunosuppression, single-cell atlas.

At its core, the chemokine system establishes nuanced concentration gradients within the TME, effectively directing T lymphocytes, natural killer cells, macrophages, and dendritic cells past formidable physiological barriers to infiltrate tumorous regions. However, their role transcends mere navigation; chemokines influence immune cell activation states, proliferation rates, and functional phenotypes through precise receptor-mediated signaling cascades. This biochemical crosstalk decisively modulates the immunological landscape, effectively toggling between immune surveillance and tumor-induced immunosuppression, thereby dictating cancer progression trajectories.

Elucidating the multifaceted impact of chemokine signals on tumor cells reveals a regulatory web that extends beyond immunity. Chemokine-receptor engagement affects malignant cell proliferation, apoptosis resistance, and phenotypic plasticity including epithelial-to-mesenchymal transition (EMT). These processes drive invasion and metastasis, challenging therapeutic efficacy. Therefore, dissecting the spatiotemporal heterogeneity and regulatory circuitry of chemokine expression within distinct tumor contexts is pivotal to crafting therapeutics capable of reshaping the notoriously immunosuppressive TME.

In a comprehensive review published in the Chinese Medical Journal on March 11, 2026, Chinese researchers have meticulously charted the chemokine expression profiles across a spectrum of malignancies, correlating these patterns with immune cell infiltration dynamics and clinical prognosis. Their synthesis underscores several innovative therapeutic methodologies harnessing the chemokine axis to potentiate antitumor immunity. Crucially, these strategies exploit the nuanced interplay between chemokine ligands and their receptors, navigating the intricacies of tumor biology to optimize immune engagement.

Foremost among these approaches is the pharmacological inhibition of immunosuppressive chemokines such as CCL2 and CXCL12. Employing small molecules or monoclonal antibodies to disrupt these signaling pathways alleviates the immunosuppressive milieu within tumors. This blockade reinvigorates the cytotoxic potential of immune effector cells and dials down factors contributing to immune evasion. By selectively targeting components of the chemokine network, this strategy promises to unshackle antitumor immunity, restoring the natural capacity of the immune system to detect and eradicate malignant cells.

Complementing inhibitory tactics are advanced delivery platforms designed to amplify immunostimulatory chemokine presence directly within tumor sites. Oncolytic viruses and antibody-drug conjugates are at the forefront of this tactic, delivering chemokines like CXCL9, CXCL10, or CCL5 with high spatial precision. This intratumoral supplementation remodels “cold” tumors—those deficient in immune cell infiltration—into “hot” tumors rich in effector lymphocytes capable of mounting a robust immune response. These delivery vehicles leverage tumor-selective tropism, thus minimizing off-target effects and maximizing therapeutic payload efficiency.

Beyond delivery, the genetic engineering of cellular therapies represents a cutting-edge frontier in chemokine axis exploitation. CAR-T and TCR-T cell therapies benefit markedly from modifications that induce overexpression of chemokine receptors, including CXCR2 and CXCR3. By enhancing sensitivity to chemokine gradients within the TME, these engineered immune cells exhibit improved homing, infiltration, and retention, overcoming one of the principal barriers to effective cell-based immunotherapies. This genetic augmentation offers a personalized approach, tailoring immune cells to the unique chemokine landscape of each patient’s tumor.

Moreover, integrating chemokine modulation with established immunotherapeutic modalities unveils synergistic possibilities to surmount therapeutic resistance. The coupling of chemokine-targeted treatments with tumor vaccines amplifies antigen-specific immune activation, boosting vaccine efficacy. Similarly, combining with immune checkpoint inhibitors, such as PD-1 or PD-L1 antagonists, addresses the challenge of insufficient immune infiltration—often a key resistance mechanism—thereby broadening the responsiveness across diverse patient populations. Adoptive cell therapy integration further enhances immune cell survival and activity, fostering the emergence of tertiary lymphoid structures that sustain long-term antitumor immunity.

The review also explores the emerging paradigm of epigenetic regulation as a modulatory lever over chemokine expression. Histone modifications and DNA methylation patterns within tumor cells and the surrounding stroma influence chemokine gene transcription, offering an additional therapeutic axis. Targeting these epigenetic mechanisms may fine-tune chemokine output, normalizing immune infiltration patterns, and mitigating adverse effects associated with systemic chemokine administration. This approach promises the development of more refined and precise interventions aligned with tumor-specific epigenomic landscapes.

Despite these promising avenues, the complexity and redundancy intrinsic to the chemokine system present substantive challenges. Tumor heterogeneity—both inter-patient and intra-tumoral—complicates the prediction of therapeutic outcomes and necessitates robust biomarker-driven stratification methods. Furthermore, the potential for systemic toxicities arising from widespread modulation of chemokine pathways mandates the design of strategies with exquisite specificity and controllability. Addressing these obstacles will require multidisciplinary efforts merging molecular biology, immunology, bioengineering, and clinical oncology.

Looking ahead, future research directives emphasize the need for deep mechanistic insights into chemokine receptor crosstalk, signaling dynamics, and context-dependent effects within the TME. Advanced tools like single-cell transcriptomics and spatial proteomics will facilitate the mapping of chemokine networks with unprecedented resolution. Translation into clinic demands well-designed clinical trials that rigorously evaluate the safety and efficacy of chemokine-targeting agents, alone and in combination, across diverse malignancies. The ultimate objective is to harness chemokine biology to reeducate the TME, tipping the balance decisively in favor of immune-mediated tumor clearance.

In summary, exploiting the chemokine–chemokine receptor axis represents a frontier in immunotherapeutic innovation, offering transformative potential for solid tumor treatment. By manipulating these cellular traffic signals, researchers aspire to reprogram the tumor ecosystem from a sanctuary for cancer cells into a battleground governed by effective immune surveillance. As this research trajectory gains momentum, chemokine-centered strategies are poised to become integral components of precision oncology, delivering renewed hope for durable and comprehensive cancer remission.

Subject of Research: Cells

Article Title: Exploiting the chemokine–chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming

News Publication Date: 11-Mar-2026

Web References: Not provided

References: DOI: 10.1097/CM9.0000000000004009

Image Credits: The Authors: Yang Zhao, Xueqian Wang, Tong Lei, Guiying Wang, Hezhe Lu, Yong Zhao

Keywords: Chemokines, tumor microenvironment, cancer immunotherapy, chemokine receptors, immune cell infiltration, CAR-T cells, immune checkpoint inhibitors, tumor vaccines, epigenetic regulation, oncolytic viruses, antibody-drug conjugates, tumor heterogeneity

HCC, a prevalent malignancy with increasing incidence worldwide, is notorious for its poor prognosis and resistance to conventional therapies. Traditional treatment regimens often fail to achieve long-term, sustained remission. However, the advent of immunotherapy, particularly therapies targeting the PD-1/PD-L1 pathway, has reshaped the treatment landscape. Despite these advances, the response rates for these therapies remain suboptimal, leading researchers to explore the tumor microenvironment’s intricacies in greater detail.

One of the critical components of the tumor microenvironment is the macrophage population. These cells play dual roles—some can promote tumor progression, while others can enhance anti-tumor immunity. The study by Meng et al. focuses particularly on SGMS2+ macrophages, a subset that has garnered attention due to its potential to stimulate immune responses. The researchers explored how these macrophages influence the infiltration of NK cells, specifically those expressing a high level of NR4A3, a transcription factor known to be crucial for NK cell function and anti-tumor activity.

Using advanced imaging and flow cytometry techniques, the study meticulously mapped the interactions between SGMS2+ macrophages and NR4A3hi NK cells within the HCC tumor microenvironment. The findings indicate that SGMS2+ macrophages secrete specific signaling molecules that not only enhance the recruitment of NR4A3hi NK cells but also improve their cytotoxic activity against tumor cells. This mechanism appears to be a promising avenue for enhancing the efficacy of PD-1 inhibitors, providing a deeper understanding of how to manipulate the immune landscape for better therapeutic outcomes.

Beyond the mechanistic insights, the researchers highlighted the potential clinical implications of their findings. By elucidating the role of SGMS2+ macrophages in NK cell infiltration, they set the stage for therapeutic strategies aimed at modulating these immune cells within the tumor. The potential to boost NK cell responses through targeted therapies could pave the way for more effective treatment methodologies that not only enhance patient prognosis but also improve the overall efficacy of existing immunotherapies.

The implications of their research stretch beyond the realm of HCC; the principles of macrophage and NK cell interaction could have broader applications across various malignancies. As cancer immunotherapy continues to evolve rapidly, understanding the immune microenvironment in a nuanced manner will be essential for developing next-generation therapeutic strategies. This study encourages researchers to consider not merely the tumor cells themselves but the multitude of interacting cells that shape the immune response and drive tumor progression.

Although the engaging aspects of macrophage biology are well acknowledged, the functionality of specific macrophage subsets, including SGMS2+ cells, remains a critical area for further exploration. The unanswered questions remain, such as the precise molecular pathways through which these macrophages exert their effects and how they might be modulated for therapeutic benefit. This research opens avenues for testing various compounds and treatments that can influence SGMS2+ macrophage activity, paving the way for innovative cancer therapies.

Furthermore, the work of Meng et al. emphasizes the need for personalized medicine in oncology. The heterogeneity observed in tumor microenvironments necessitates tailored therapeutic options based on individual patient profiles. By identifying specific macrophage activities associated with favorable NK cell recruitment and function, oncologists may one day leverage this information to select the most promising treatment regimens for patients with HCC.

As the landscape of cancer treatment continues to evolve, continued collaboration between basic researchers and clinical oncologists will be crucial to translating these findings into practice. By moving swiftly from bench to bedside, the insights gained from such studies can lead to practical applications that significantly alter the course of treatment for patients battling hepatocellular carcinoma. The call to focus on immune dynamics represents a paradigm shift in cancer therapy, urging researchers and healthcare professionals to consider innovative strategies that target immune modulatory pathways.

Finally, the study lays down a critical framework for future clinical trials focusing on SGMS2+ macrophage-targeting therapies in combination with existing PD-1 inhibitors. With a deeper knowledge of how to effectively mobilize the immune system against HCC, the potential for improved patient outcomes becomes increasingly tangible. It is evident that studies such as this play an instrumental role in the ongoing quest to overcome the formidable challenges posed by cancer treatment.

In conclusion, the imperative of developing novel cancer therapeutics is underscored by findings from Meng, Nian, Feng, and colleagues. Their exploration into SGMS2+ macrophages and their capacity to enhance NR4A3hi NK cell responses not only provides hope for significantly improving hepatocellular carcinoma prognosis but shines light on broader immunological principles that can be harnessed across multiple tumors. Thus, the journey towards better cancer therapies is one of collective inquiry and interdisciplinary collaboration—critical elements that will ultimately drive innovation and improve the lives of countless patients faced with the challenges of cancer.

Subject of Research: Interaction of SGMS2+ macrophages and NR4A3hi NK cells in hepatocellular carcinoma.

Article Title: SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma.

Article References:

Meng, F., Nian, F., Feng, H. et al. SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07040-x

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07040-x

Keywords: hepatocellular carcinoma, immunotherapy, NK cells, SGMS2+ macrophages, PD-1 inhibitors, cancer treatment, tumor microenvironment.